

表 19 卵子・卵巣機能に悪影響を与える抗がん剤

リスク発生頻度	抗がん剤
common	シクロホスファミド
possible	シスプラチン
	カルボプラチン
	ビンブラスチン
	エトポシド
	アクチノマイシン D
rare	ドキソルビシン
	ビンクリスチン
	メソトレキセート
	5-フルオロウラシル
	ブレオマイシン
no data	バクリタキセル
	ドセタキセル
	イホスファミド
	ジェムシタビン

The Chemotherapy Source Book 第3版 (Michael C. Perry 編
Lippincott Williams & Wilkins 社 平成13年発行) より引用, 一部改変

第4章 ■ 資料集

I 抗がん剤の副作用一覧

（医薬品インタビューフォームより抜粋）

商品名 (一般名)	症例数	副作用 発現率 (%)	血液			消化器			
			白血球 減少	Hb 減少	血小板 減少	悪心・ 嘔吐	食欲 不振	下痢	腹痛
ランダ ブリプラチン (シスプラチン)	市販後調査 7,448 例	83.9%	35.6%	27.2%	16.3%	72.7%	59.9%	5.7%	0.5%
パラプラチン (カルボプラチン)	市販後調査 5,598 例	85.7%	57.2%	40.4%	41.9%	50.6%	46.0%	3.3%	2.3%
タキソール (パクリタキセル)	第2相臨床試験 477 例	-	91.8%	76.1%	11.1%	36.9%	5.2%	14.0%	-
タキソテール (ドセタキセル)	第2相臨床試験 865 例	-	97.2%	53.4%	12.4%	47.9%	58.7%	22.5%	3.4%
トポテシン カンプト (塩酸イリノテカン)	市販後調査 15,385 例	-	73.1%	57.3%	28.0%	52.5%	48.1%	43.0%	12.2%
エンドキサン (シクロホスファミド)	103 論文より集計 5,021 例	-	37.9%	2.3%	6.1%	20.7%	3.8%	0.5%	0.1%
アドリアシン (塩酸ドキソルビシン)	市販後調査 768 例	91.8%	49.7%	17.6%	16.8%	58.2%	54.7%	6.4%	0.7%
ピノルビン テラルビシン (塩酸ピラルビシン)	承認時, 市販後調査 3,591 例	71.2%	50.4%	-	14.5%	31.9%	36.4%	2.5%	-
ファルモルビシン (塩酸エピルビシン)	承認時, 市販後調査 4,818 例	56.7%	33.6%	20.3%	13.3%	36.7%	24.5%	1.9%	0.5%
ベプシド ラストット (エトボシド)	市販後調査 4,025 例	88.1%	68.1%	50.4%	47.7%	40.1%	49.6%	5.7%	2.5%
ブレオ (塩酸ブレオマイシン)	承認時, 市販後調査 1,613 例	-	0.2%	0.2%	0%	14.6%	28.7%	1.2%	-

I. 抗がん剤の副作用一覧 59

肝臓	腎臓	呼吸器	神経系	皮膚付属器	その他の副作用および注意事項
GOT/GPT上昇 肝機能障害	BUN/Cr上昇 Ccr低下	間質性肺炎	末梢神経障害	脱毛	
9.5%/10.3% -	13.0%/6.1% 9.8%	0.1%	1.5%	26.0%	聴覚障害(1.4%), 視覚障害(うっ血乳頭, 球後視神経炎, 皮質盲; 0.1%未満)
9.1%/10.2% -	5.2%/2.6% 3.7%	0.1% 未満	0.46%	20.2%	アナフィラキシー
35.6%/40.7% -	9.9%/5.3% -	1.3%	65.1%	83.6%	発熱(42.3%), 関節痛(40.3%), 筋肉痛(36.3%), 過敏症・発赤(13.8%), 心電図異常(2.2%)
20.3%/19.9% -	4.6%/1.6% -	0.1%	9.4%	76.8%	発熱(45.9%), 浮腫(8.0%), アレルギー(6.8%), 心タンポナーデ, 体液貯留, イレウス, 急性膵炎(頻度不明)
- 1.2%	- -	0.9%	-	-	腸管麻痺(1.6%), イレウス(0.4%) 高度な骨髓機能抑制の持続による重症感染症および高度な下痢の持続による脱水, 電解質異常, 循環不全に注意
- 1.0%	- -	-	-	24.3%	出血性膀胱炎(1.2%), 排尿障害(2.3%), 血尿(2.0%) 卵巣毒性, 抗利尿ホルモン不適合分泌症候群(SIADH)
- 7.3%	- 0.5%	-	-	73.2%	心筋障害, 心電図異常(9.8%) 総投与量 500mg/m ² 以上で重篤な心筋障害に注意
- 5.8%	- 2.0%	0.1% 未満	-	21.5%	心筋障害(0.1~5% 未満), 心電図異常(4.3%) 総投与量 950mg/m ² 以上でうっ血性心不全に注意
- 6.8%	- 1.2%	-	0.02%	24.2%	心筋障害(0.12%), 心電図異常(0.48%) 総投与量 950mg/m ² 以上でうっ血性心不全に注意
10.5%/12.2% -	5.6%/2.8% 0.22%	0.02%	0.89%	44.4%	二次発癌(急性白血病, 骨髓異形成)
- 0.2%	- -	10.2%	-	29.5%	皮膚の硬化, 色素沈着(40.6%), 発熱(39.8%), 口内炎(13.3%) 60歳以上の高齢者では間質性肺炎・肺線維症に特に注意

(-は記載なし)

II 略語一覧

AGO	Arbeitsgemeinschaft Gynaekologische Onkologie
AGO-GINECO OVAR7	Arbeitsgemeinschaft Gynakologische Onkologie - Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
AUC	area under the concentration-time curve
CAP	cyclophosphamide, doxorubicin (adriamycin) and cisplatin
cCR	clinical complete response
CJ	cyclophosphamide and JM-8 (carboplatin)
CP	cyclophosphamide and cisplatin
CR	complete response
CSF	colony stimulating factor
CT	computed tomography
DFI	disease-free interval
DJ	docetaxel and JM-8 (carboplatin)
ECOG	Eastern Cooperative Oncology Group
EORTC	European Organization Research of Treatment of Cancer
FIGO	International Federation of Gynecology and Obstetrics
FN	febrile neutropenia
Ga シンチグラム	gallium シンチグラム
G-CSF	granulocyte-colony stimulating factor
GFR	glomerular filtration rate
GINECO	Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
GOG	Gynecologic Oncology Group
GONO	Gruppo Oncologico Nord-Ouest
HSR	hypersensitive reaction
ICON	International Collaborative Ovarian Neoplasm Study
IDS	interval debulking surgery
ip	intraperitoneal
IRB	Institutional Review Board
iv	intravenous
IVP	intravenous pyelography
JP	JM-8 (carboplatin) and cisplatin
M-CSF	macrophage-colony stimulating factor
MRI	magnetic resonance imaging
MS	median survival
MST	median survival time
NAC	neo-adjuvant chemotherapy
NCCN	National Comprehensive Cancer Network
NIH	National Institutes of Health
NS	not significant
OS	overall survival

PALA	para-aortic lymphadenectomy
PBSCT	peripheral blood stem cell transplantation
pCR	pathological complete response
PFI	progression-free interval
PFS	progression-free survival
PLA	pelvic lymphadenectomy
PR	partial response
PS	performance status
PtFI	platinum-free interval
QOL	quality of life
RR	response rate
SCOTROC	Scottish Randomized Trial in Ovarian Cancer
SDS	secondary debulking surgery
SEER	Surveillance, Epidemiology, and End Results (National Cancer Institute)
SLO	second look operation
SLO/SDS	second look operation/secondary debulking surgery
SWOG	Southwest Oncology Group
TJ	taxol (paclitaxel) and JM-8 (carboplatin)
TP	taxol (paclitaxel) and cisplatin
WHO	World Health Organization
51Cr EDTA	51Cr ethylenediaminetetraacetic acid
95%CI	95% confidential interval

Ⅲ 引用文献

第1章 ガイドライン総論

- 1) 有吉寛. 抗がん剤適正使用ガイドライン(案): 厚生省(現厚生労働省)委託事業における「抗がん剤適正使用のガイドライン」(案)の開示に際して. 癌と化学療法 2002; 29: 969-77.
- 2) 落合和徳, 岡本愛光, 勝俣範之. 抗がん剤適正使用ガイドライン(案): 婦人科癌. 癌と化学療法 2002; 29: 1047-54.

第2章 上皮性卵巣腫瘍

I. 概論

- 1) 平成7年人口動態統計 厚生省大臣官房統計情報部編 財団法人厚生省統計協会 1995; 3: 343.
- 2) Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6: 107-38.
- 3) 婦人科腫瘍委員会報告. 2000年度卵巣腫瘍患者年報. 日産婦誌 2004; 56: 91-114.
- 4) Trimble EL, Christian MC, Kosay C. Surgical debulking plus paclitaxel-based adjuvant chemotherapy superior to previous ovarian cancer therapies. Oncology 1999; 13: 1068.
- 5) McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
- 6) Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.

II. 卵巣癌の治療—フローチャートとその解説—

- 1) Ovarian Cancer Guideline (Version 1.2002). National Comprehensive Cancer Network.
- 2) Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072-6.
- 3) Buchsbaum HJ, Brady MF, Delgado G, Miller A, Hoskins WJ, Manetta A, et al. Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989; 169: 226-32.
- 4) Helewa ME, Krepert GV, Lotocki R. Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol 1986; 154: 282-6.
- 5) Archer JC, Soeters RP, Bloch B, Dehaeck CM, Levin W. Repeat laparotomy in ovarian carcinoma after primary surgery. S Afr Med J 1991; 80: 276-7.
- 6) Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-Pearson DL. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 1992; 80: 949-53.
- 7) Faught W, Lotocki RJ, Heywood M, Krepert GV. Early ovarian cancer: Value of a negative staging laparotomy. Eur J Gynaecol Oncol 1996; 17: 200-3.
- 8) Faught W, Le T, Fung Kee Fung M, Krepert G, Lotocki R, Heywood M. Early ovarian cancer: what is the staging impact of retroperitoneal node sampling? J Obstet Gynaecol Can 2003; 25: 18-21.
- 9) Young RC, Brady MF, Walton LA, Homesley HD, Averette HE, Long HJ. Localized ovarian cancer in the elderly. The Gynecologic Oncology Group experience. Cancer 1993; 71: 601-5.
- 10) Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-9.
- 11) Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-59.
- 12) Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol

- Scand 1971 ; 50 : 1-7.
- 13) Serov SF, Scully RE, Sobin LH, editors. Histological typing of ovarian tumours. (International histological classification of tumours. No.9). Geneva : World Health Organization 1973 ; 17-54.
 - 14) Benda JA, Zaino R. GOG pathology manual. Buffalo, NY : Gynecologic Oncology Group, 1994. <http://www.vh.org/adult/provider/pathology/OBGYN/Oncology/PathologyManualHom>.
 - 15) Silverberg SG. Histopathologic grading of ovarian carcinoma : A review and proposal. Int J Gynecol Pathol 2000 ; 19 : 7-15.
 - 16) Ishioka S, Sagae S, Terasawa K, Sugimura M, Nishioka Y, Tsukada K, et al. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol 2003 ; 89 : 447-52.
 - 17) Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990 ; 322 : 1021-7.
 - 18) Monga M, Carmichael JA, Shelley WE, Kirk ME, Krepart GV, Jeffrey JF, et al. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 1991 ; 43 : 195-7.
 - 19) Trimbos JB, Schueler JA, van der Burg M, Hermans J, van Lent M, Heintz AP, et al. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 1991 ; 67 : 597-602.
 - 20) Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma : European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003 ; 95 : 113-25.
 - 21) Simojoki M, Santala M, Vuopala S, Kauppila A. The prognostic value of peritoneal cytology in ovarian cancer. Eur J Gynaecol Oncol 1999 ; 20 : 357-60 .
 - 22) Sainz de la Cuesta R, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994 ; 84 : 1-7.
 - 23) Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelde P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001 ; 357 : 176-82.
 - 24) Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Suzuki T, Ino K, et al. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 2003 ; 65 : 29-36.
 - 25) Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990 ; 75 : 263-73.
 - 26) Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Trope CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma : importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993 ; 169 : 40-52.
 - 27) Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996 ; 14 : 2968-75.

Ⅲ. 手術療法

A. 手術の適応

- 1) Conway C, Zalud I, Dilena M, Maulik D, Schulman H, Haley J, et al. Simple cyst in the postmenopausal patients : Detection and management. J Ultrasound Med 1998 ; 17 : 369-72.
- 2) Goldstein SR, Subramanyam B, Snyder JR, Beller U, Raghavendra BN, Beckman EM . The postmenopausal cystic adnexal mass : The potential role of ultrasound in conservative management. Obstet Gynecol 1989 ; 73 : 8-10.
- 3) Wolf SI, Gosink BB, Feldesman MR, Lin MC, Stuenkel CA, Braly PS, et al. Prevalence of simple adnexal cysts in postmenopausal women. Radiology 1991 ; 180 : 65-71.

- 4) Andolf E, Jorgensen C. Cystic lesions in elderly women, diagnosed by ultrasound. *Br J Obstet Gynaecol* 1989 ; 96 : 1076-9.
- 5) 落合和徳, 大村峯夫. 更年期女性における卵巣癌スクリーニング-特に経膈超音波診断の有用性について, *産婦人科の世界* 1995 ; 47 : 465-70.
- 6) DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, et al. A morphology index based on sonographic findings in ovarian cancer. *Gynecol Oncol* 1993 ; 51 : 7-11.
- 7) 大沼一也, 小林久晃, 笹秀典, 吉田純, 小松要介, 小林充尚, 他. 卵巣腫瘍の画像診断精度-経腹・経膈超音波断層法, CT, MRI 4者画像診断の比較検討- . *日産婦関東連会報* 1993 ; 30 : 5-10.
- 8) 虎島みゆき, 山下康行, 畑中義美, 高橋睦正, 宮崎康二, 岡村均. 卵巣癌の進展範囲 CT と MRI による検討. *日磁医誌* 1995 ; 15 : 275-82.
- 9) 加藤紘. 腫瘍マーカーとその選び方. *産婦人科治療* 1992 ; 64 : 428-31.
- 10) 伊藤高太郎, 宇田川康博, 野澤志朗. 婦人科腫瘍における腫瘍マーカー陽性率. *産と婦* 1993 ; 60 : 260-65.

B. 手術の目的

- 1) Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet U, Creasman W, et al. FIGO annual report on the results of treatment in gynaecological cancer-Carcinoma of the ovary. *J Epidemiol Biostatist* 2002 ; 6 : 107-38.
- 2) Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group : Age is not an independent prognostic factor. *Cancer* 1996 ; 77 : 1131-6.
- 3) Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. *Cancer* 1993 ; 71 : 606-14.
- 4) Hogberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. *Gynecol Oncol* 1993 ; 48 : 38-49.
- 5) Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A. National survey of ovarian carcinoma VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. *Cancer* 1993 ; 72 : 3007-11.
- 6) Duska LR, Chang YuC, Flynn CE, Chen AH, Goodman A, Fuller AF, et al. Epithelial ovarian carcinoma in the reproductive age group. *Cancer* 1999 ; 85 : 2623-9.
- 7) Sainz de la Cuesta R, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. *Obstet Gynecol* 1994 ; 84 : 1-7.
- 8) Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. *Obstet Gynecol* 1990 ; 75 : 263-73.
- 9) Partridge EE, Gunter BC, Gelder MS, Alvarez RD, Soong SJ, Austin JM, et al. The validity and significance of substages of advanced ovarian cancer. *Gynecol Oncol* 1993 ; 48 : 236-41.
- 10) Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. *Ann Oncol* 1991 ; 2 : 281-7.
- 11) Makar AP, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. *Gynecol Oncol* 1995 ; 56 : 175-80.
- 12) Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. *Obstet Gynecol* 1983 ; 61 : 413-20.
- 13) Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer : The role of maximal surgical reduction. *Gynecol Oncol* 1984 ; 18 : 293-8.
- 14) Baiocchi G, Raspagliesi F, Grosso G, Fontanelli R, Cobellis L, di Re E, et al. Early ovarian cancer : Is there a role for systematic pelvic and para-aortic lymphadenectomy? *Int J Gynecol Cancer* 1998 ; 8 : 103-8.
- 15) Kanazawa K, Suzuki T, Takashiki M. The validity and significance of substage IIIc by node involvement in epithelial ovarian cancer : Impact of nodal metastasis on patient survival. *Gynecol Oncol* 1999 ; 73 : 237-41.

- 16) van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. *N Engl J Med* 1995 ; 332 : 629-34.
 - 17) Ovarian Cancer Guideline (Version 1.2002) . National Comprehensive Cancer Network.
 - 18) Di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer : prognostic significance of node metastases. *Gynecol Oncol* 1996 ; 62 : 360-5.
 - 19) Carnino F, Fuda G, Ciccone G, Iskra L, Guercio E, Dadone D, et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. *Gynecol Oncol* 1997 ; 65 : 467-72.
 - 20) Tsumura N, Sakuragi N, Hareyama H, Satoh C, Oikawa M, Yamada H, et al. Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. *Int J cancer* 1998 ; 79 : 526-30.
 - 21) Baiocchi G, Grosso G, di Re E, Fontanelli R, Paspagliesi F, di Re F. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. *Gynecol Oncol* 1998 ; 69 : 151-6.
 - 22) Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to stage I / II patients and superior survival to other stage III patients. *Cancer* 1998 ; 83 : 1555-60.
 - 23) Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. *N Engl J Med* 1990 ; 322 : 1021-7.
 - 24) O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid) : bad prognosis only in early stages. *Gynecol Oncol* 1993 ; 49 : 250-4.
 - 25) Brugghe J, Baak JP, Wiltshaw E, Fisher C. Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment. *Int J Gynecol Cancer* 1995 ; 5 : 262-8.
 - 26) Jacobs AJ, Deligdisch L, Deppe G, Cohen CJ. Histologic correlates of virulence in ovarian adenocarcinoma. I. Effect of differentiation. *Am J Obstet Gynecol* 1982 ; 143 : 574-80.
 - 27) Baak JP, Chan KK, Stolk JG, Kenemans P. Prognostic factors in borderline and invasive ovarian tumors of the common epithelial type. *Pathol Res Pract* 1987 ; 182 : 755-74.
 - 28) Silverberg SG. Prognostic significance of pathologic features of ovarian carcinoma. *Curr Top Pathol* 1989 ; 78 : 85-109.
 - 29) Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma I. Prognostic significance of histopathologic features problems involved in the architectural grading system. *Gynecol Oncol* 1998 ; 70 : 2-12.
 - 30) Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Trope CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma : importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. *Am J Obstet Gynecol* 1993 ; 169 : 40-52.
 - 31) Yazdi GP, Miedema BW, Humphrey LJ. High mortality after abdominal operation in patients with large-volume malignant ascites. *J Surg Oncol* 1996 ; 62 : 93-6.
- C. 手術用語
- 1) Silberman AW. Surgical debulking of tumors. *Surg Gynecol Obstet* 1982 ; 155 : 577-85.
 - 2) Berek JS. Interval debulking of ovarian cancer-an interim measure. *N Engl J Med* 1995 ; 332 : 675-7.
- D. 手術手技
- 1) Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. *JAMA* 1983 ; 250 : 3072-6.
 - 2) Buchsbaum HJ, Brady MF, Delgado G, Miller A, Hoskins WJ, Manetta A, et al. Surgical

- staging of carcinoma of the ovaries. *Surg Gynecol Obstet* 1989 ; 169 : 226-32.
- 3) Knapp RC, Friedman EA. Aortic lymph node metastases in early ovarian cancer. *Am J Obstet Gynecol* 1974 ; 119 : 1013-7.
 - 4) Delgado G, Chun B, Caglar H, Bepko F. Paraaortic lymphadenectomy in gynecologic malignancies confined to the pelvis. *Obstet Gynecol* 1977 ; 50 : 418-23.
 - 5) Priver MS, Barlow JJ, Lele SB. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. *Obstet Gynecol* 1978 ; 52 : 100-4.
 - 6) Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease : A Gynecologic Oncology Group study. *Proc ASCO* 2002 ; 21 : 201a (802) .
 - 7) De Poncheville L, Perrotin F, Lefrancg T, Lansac J, Body G. Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries? *Eur J Cancer* 2001 ; 37 : 210-5.
 - 8) Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer : Status of the art at the end of the second millennium. *Int J Gynecol Cancer* 2000 ; 10 : 435-42.
 - 9) Obermair A, Sevelde P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. *Acta Obstet Gynecol Scand* 2001 ; 80 : 432-6.
 - 10) Pickel H, Lahousen M, Stettner H, Girardi F. The spread of ovarian cancer. *Baillieres Clin Obstet Gynaecol* 1989 ; 3 : 3-12.
 - 11) Rosenoff SH, DeVita T Jr, Hubbard S, Young RC. Peritoneoscopy in the staging and follow-up of ovarian cancer. *Semin Oncol* 1975 ; 2 : 223-8.
 - 12) Malfetano JH. The appendix and its metastatic potential in epithelial ovarian cancer. *Obstet Gynecol* 1987 ; 69 : 396-8.
 - 13) Rose PG, Reale FR, Fisher A, Hunter RE. Appendectomy in primary and secondary staging operations for ovarian malignancy. *Obstet Gynecol* 1991 ; 77 : 116-8.
 - 14) Fontanelli R, Paladini D, Raspagliesi F, Di Re E. The role of appendectomy in surgical procedures for ovarian cancer. *Gynecol Oncol* 1992 ; 46 : 42-4.
 - 15) Ayhan A, Tuncer ZS, Tuncer R, Yuce K, Kucukali T. Is routine appendectomy beneficial in the management of ovarian cancer? *Eur J Obstet Gynecol Reprod Biol* 1994 ; 57 : 29- 31.
 - 16) Carnino F, Fuda G, Ciccone G, Iskra L, Guercio E, Dadone D, et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. *Gynecol Oncol* 1997 ; 65 : 467-72.
 - 17) Di Re F, Fontanelli R, Raspagliesi F, Di Re E. Pelvic and paraaortic lymphadenectomy in cancer of the ovary. *Bailliere's Clin Obstet Gynecol* 1989 ; 3 : 131-42.
 - 18) Benedetti-Panici P, Greggi S, Maneschi F, Scambia G, Amoroso M, Rabitti C, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. *Gynecol Oncol* 1993 ; 51 : 150-4.
 - 19) Wu PC, Lang JH, Huang RL, Qu JY, Wang H, Tang MY, et al. Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer. *Bailliere's Clin Obstet Gynecol* 1989 ; 3 : 143-55.
 - 20) Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. *Gynecol Oncol* 1991 ; 40 : 103-6.
 - 21) Petru E, Lahousen M, Tamussino K, Pickel H, Stranzl H, Stettner H, et al. Lymphadenectomy in stage I ovarian cancer. *Am J Obstet Gynecol* 1994 ; 170 : 656-62.
 - 22) Onda T, Yoshikawa H, Yokota H, Yasugi T, Taketani Y. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. *Cancer* 1996 ; 78 : 803-8.
 - 23) Tsuruchi N, Kamura T, Tsukamoto N, Akazawa K, Saito T, Kaku T, et al. Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer-a multivariate analysis. *Gynecol Oncol* 1993 ; 49 : 51-5.
 - 24) Chen SS, Lee L. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. *Gynecol Oncol* 1983 ; 16 : 95-100.
 - 25) Lanza A, Daddato F, Valli M, Bussone R, Caldarola B, Re A, et al. Pelvic and para-aortic lymph nodal positivity in the ovarian carcinoma : its prognostic significance. *Eur J Gynecol*

- Oncol 1988 ; 1 : 36-9.
- 26) Zanetta G, Chiari S, Barigozzi P, Rota S, Losa G, Mangioni C. Limited invasiveness to assess retroperitoneal spread in stage I-II ovarian carcinoma. *Int J Gynecol Obstet* 1995 ; 51 : 133-40.
 - 27) Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. *Gynecol Oncol* 2001 ; 80 : 56-61.
 - 28) Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fujino T, Sagawa T, et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). *Gynecol Oncol* 2000 ; 79 : 251-5.
 - 29) Suzuki M, Ohwada M, Yamada T, Kohno T, Sekiguchi I, Sato I. Lymph node metastasis in stage I epithelial ovarian cancer. *Gynecol Oncol* 2000 ; 79 : 305-8.
 - 30) Baiocchi G, Raspagliesi F, Grosso G, Fontanelli R, Cobellis L, di Re E, et al. Early ovarian cancer : Is there a role for systematic pelvic and para-aortic lymphadenectomy? *Int J Gynecol Cancer* 1998 ; 8 : 103-8.
 - 31) Kanazawa K, Suzuki T, Takashiki M. The validity and significance of substage IIIc by node involvement in epithelial ovarian cancer : Impact of nodal metastasis on patient survival. *Gynecol Oncol* 1999 ; 73 : 237-41.

E. 腫瘍減量手術

- 1) Kanazawa K, Suzuki T, Takashiki M. The validity and significance of substage IIIc by node involvement in epithelial ovarian cancer : Impact of nodal metastasis on patient survival. *Gynecol Oncol* 1999 ; 73 : 237-41.
- 2) Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. *Gynecol Oncol* 1991 ; 42 : 146-50.
- 3) Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease : A Gynecologic Oncology Group study. *Proc ASCO* 2002 ; 21 : 201a (802).
- 4) Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. *Br J Obstet Gynecol* 1994 ; 101 : 142-6.
- 5) Tay EH, Grant PT, GebSKI V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. *Obstet Gynecol* 2002 ; 99 : 1008-13.
- 6) Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. *Gynecol Oncol* 2001 ; 83 : 504-12.
- 7) Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. *Cancer* 1995 ; 76 : 1606-14.
- 8) Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. *J Clin Oncol* 1993 ; 3 : 434-9.
- 9) Munkarah A, Levenback C, Wolf JK, Bodurka-Bervers D, Tortolero-Luna G, Morris RT, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. *Gynecol Oncol* 2001 ; 81 : 237-41.
- 10) Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrone L, Saigo P, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. *Gynecol Oncol* 1989 ; 34 : 365-71.
- 11) Morris M, Gershenson DM, Wharton TJ, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. *Gynecol Oncol* 1989 ; 34 : 334-8.
- 12) Free KE, Webb MJ. Second-look laparotomy-clinical correlations. *Gynecol Oncol* 1987 ; 26 : 290-7.
- 13) van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. *N Engl J Med* 1995 ; 332 : 629-34.

- 14) Walton L, Ellenberg SS, Major F Jr, Miller A, Park R, Young RC. Results of second-look laparotomy in patients with early-stage ovarian carcinoma. *Obstet Gynecol* 1987 ; 70 : 770-3.

F. セカンドルック

- 1) Obermair A, Sevelde P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. *Acta Obstet Gynecol Scand* 2001 ; 80 : 432-6.
- 2) Chambers SK, Chambers JT, Kohorn EI, Lawrence R, Schwartz PE. Evaluation of the role of second-look surgery in ovarian cancer. *Obstet Gynecol* 1988 ; 72 : 404-8.
- 3) Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM Jr, Shingleton HM. Second-look laparotomy and salvage therapy : A research modality only? *Gynecol Oncol* 1992 ; 44 : 3-9.
- 4) Hainsworth JD, Grosh WW, Burnett LS, Jones HW 3rd, Wolff SN, Greco FA. Advanced ovarian cancer : long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. *Ann Intern Med* 1988 ; 108 : 165-70.
- 5) Tuxen MK, Strauss G, Lund B, Hansen M. The role of second-look laparotomy in the long-term survival in ovarian cancer. *Ann Oncol* 1997 ; 8 : 643-8.
- 6) Creasman WT. Second-look laparotomy in ovarian cancer. *Gynecol Oncol* 1994 ; 55 : S122-7.
- 7) Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, et al. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration. *Cancer* 1988 ; 61 : 2571-7.
- 8) Nicoletto MO, Tumolo S, Talamini R, Salvagno L, Franceschi S, Visona E, et al. Surgical second look in ovarian cancer : a randomized study in patients with laparoscopic complete remission-Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. *J Clin Oncol* 1997 ; 15 : 994-9.
- 9) Morris M, Gershenson DM, Wharton TJ, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. *Gynecol Oncol* 1989 ; 34 : 334-8.
- 10) Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA, Long HJ, et al. Evaluation of treatment and survival after positive second-look laparotomy. *Gynecol Oncol* 1988 ; 31 : 9-24.
- 11) Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson J, DeGeest K, et al. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. *Gynecol Oncol* 1990 ; 36 : 43-7.
- 12) Hempling RE, Wesolowski JA, Piver MS. Second-look laparotomy in advanced ovarian cancer : a critical assessment of morbidity and impact on survival. *Ann Surg Oncol* 1997 ; 4 : 349-54.
- 13) Williams L, Brunetto VL, Yordan E, DiSaia PJ, Creasman WT. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer : a Gynecologic Oncology Group Study. *Gynecol Oncol* 1997 ; 66 : 171-8.
- 14) Friedman RL, Eisenkop SM, Wang HJ. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. *Gynecol Oncol* 1997 ; 67 : 88-94.
- 15) Dauplat J, Ferriere JP, Gorbinet M, Legros M, Chollet P, Giraud B, et al. Second-look laparotomy in managing epithelial ovarian carcinoma. *Cancer* 1986 ; 57 : 1627-31.
- 16) Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer : a DACOVA study. *Gynecol Oncol* 1990 ; 38 : 203-9.
- 17) Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. *Cancer* 1992 ; 72 : 2129-36.
- 18) Podratz KC, Malkasian GD Jr, Hilton JF, Harris EA, Gaffey TA. Second-look laparotomy in ovarian cancer : evaluation of pathologic variables. *Am J Obstet Gynecol* 1985 ; 152 : 230-8.
- 19) Walton L, Ellenberg SS, Major F Jr, Miller A, Park R, Young RC. Results of second-look laparotomy in patients with early-stage ovarian carcinoma. *Obstet Gynecol* 1987 ; 70 : 770-

- 3.
 - 20) 西村治夫, 大蔵尚文, 薬師寺道明, 寺島芳輝, 木村英三, 藤本征一郎, 他. 卵巣癌に対する Second look operation (SLO) の評価—287 例を対象として—. 日癌治療会誌 1995 ; 30 : 1721-8.
 - 21) 高倉聡, 落合和徳, 塩塚重正, 新家秀, 磯西成治, 木村英三, 他. 卵巣癌根治術後のセカンドルック手術の意義. 日産婦誌 1998 ; 50 : 111-8.
 - 22) Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N, Edwards CL, et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. *Cancer* 1985 ; 55 : 1129-35.
 - 23) Gall S, Bundy B, Beecham J, Whitney C, Homesley H, Lifshitz S, et al. Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus *Corynebacterium parvum*. *Gynecol Oncol* 1986 ; 25 : 26-36.
 - 24) Podratz KC, Malkasian GD Jr, Wieand HS, Cha SS, Lee RA, Stanhope CR, et al. Recurrent disease after negative second look laparotomy in stage III and IV ovarian carcinoma. *Gynecol Oncol* 1988 ; 29 : 274-82.
 - 25) Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, et al. Predictive factors for long-term survival in patients with advanced ovarian cancer. *Gynecol Oncol* 1989 ; 34 : 88-93.
 - 26) Gallion HH, Hunter JE, van Nagell JR, Averette HE, Cain JM, Copeland LJ, et al. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. *Gynecol Oncol* 1992 ; 46 : 29-32.
 - 27) Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. *Cancer* 1986 ; 57 : 1725-30.
 - 28) Luesley DM, Chan KK, Lawton FG, Blackledge GR, Mould JM. Survival after negative second-look laparotomy. *Eur J Surg Oncol* 1989 ; 15 : 205-10.
 - 29) Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman M, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. *Gynecol Oncol* 1991 ; 42 : 137-41.
 - 30) Maggino T, Gadducci A, Romagnolo C, Fanucchi A, Fioretti P. Times and sites of relapses after negative second look in advanced epithelial ovarian cancer. *Eur J Surg Oncol* 1994 ; 20 : 146-50.
 - 31) Free KE, Webb MJ. Second-look laparotomy-clinical correlations. *Gynecol Oncol* 1987 ; 26 : 290-7.
 - 32) Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrone L, Saigo P, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. *Gynecol Oncol* 1989 ; 34 : 365-71.
- G. 内視鏡手術
- 1) NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. *JAMA*. 1995 ; 273 : 491-7.
 - 2) Leminen A, Lehtovirta P. Spread of ovarian cancer after laparoscopic surgery : report of eight cases. *Gynecol Oncol*, 1999 ; 75 : 387-90.
 - 3) Hopkins MP, Dulai RM, Occhino A, Holda S. The effects of carbon dioxide pneumoperitoneum on seeding of tumor in port sites in a rat model. *Am J Obstet Gynecol*. 1999 ; 181 : 1329-33.
 - 4) Watson DI, Mathew G, Ellis T, Baigrie CF, Rofe AM, Jamieson GG. Gasless laparoscopy may reduce the risk of port-site metastases following laparoscopic tumor surgery. *Arch Surg*. 1997 ; 132 : 166-8.
- H. 妊孕性温存
- 1) Duska LR, Chang YuC, Flynn CE, Chen AH, Goodman A, Fuller AF, et al. Epithelial ovarian carcinoma in the reproductive age group. *Cancer* 1999 ; 85 : 2623-9.
 - 2) DiSaia PJ, Creasman WT. Management of early ovarian cancer in young women. In :

- DiSaia PJ, Creasman WT, editors. *Clinical Gynecologic Oncology*. 6th ed. St. Louis, Mosby 2002 ; 279-82.
- 3) Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. *Cancer* 1993 ; 71 : 1810-20.
 - 4) Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G. Borderline tumors of the ovary : fertility treatment, conservative management, and pregnancy outcome. *Cancer* 1998 ; 82 : 141-6.
 - 5) Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors) . A long-term follow up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. *Cancer* 1996 ; 78 : 278-86.
 - 6) Zanetta G, Rota S, Chiari S, Bonnazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma : a prospective study. *J Clin Oncol* 2001 ; 19 : 2658-64.
 - 7) Jobo T, Yonaha H, Iwaya H, Kanai T, Kuramoto H. Conservative surgery for malignant ovarian tumor in women of childbearing age. *Int J Clin Oncol* 2000 ; 5 : 41-7.
 - 8) Morice P, Wicart-Poque F, Rey A, El-Hassan I, Pautier P, Lhomme C, et al. Results of conservative treatment in epithelial ovarian carcinoma. *Cancer* 2001 ; 92 : 2412-8.
 - 9) Sugiyama T, Tamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary : a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. *Cancer* 2000 ; 88 : 2584-9.
 - 10) Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. *J Clin Oncol* 1996 ; 14 : 2968-75.
 - 11) Zanetta G, Chiaris S, Rota S, Bratina G, Maneo A, Torri V, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. *Br J Obstet Gynecol* 1997 ; 104 : 1030-5.
 - 12) Williams TJ, Dockerty MB. Status of contralateral ovary in encapsulated low grade malignant tumors of the ovary. *Surg Gynecol Obstet* 1976 ; 143 : 763-6.
 - 13) Eddy CA, Asch RH, Balmaceda JP. Pelvic adhesions following microsurgical and macrosurgical wedge resection of the ovaries. *Fertil Steril* 1980 ; 33 : 557-61.
 - 14) Munnell EW. Is conservative therapy ever justified in stage I (IA) cancer of the ovary. *Am J Obstet Gynecol* 1969 ; 103 : 641-53.
 - 15) Suzuki M, Ohwada M, Yamada T, Kohno T, Sekiguchi I, Sato I. Lymph node metastasis in stage I epithelial ovarian cancer. *Gynecol Oncol* 2000 ; 79 : 305-8.
 - 16) Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, et al. Lymph node involvement in epithelial ovarian cancer : analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. *J Am Coll Surg* 2003 ; 197 : 198-205.
 - 17) De Poncheville L, Perrotin F, Lefrancq T, Lansac J, Body G. Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries? *Eur J Cancer* 2001 ; 37 : 210-5.
 - 18) Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fujino T, Sagawa T, et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0) . *Gynecol Oncol* 2000 ; 79 : 251-5.

IV. 化学療法

B. 寛解導入・補助

- 1) Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. *Cancer* 1986 ; 57 : 1725-30.
- 2) West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma : a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and

- cyclophosphamide. *Eur J Gynaecol Oncol* 1997 ; 18 : 343-8.
- 3) McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996 ; 334 : 1-6.
 - 4) Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year results. *J Natl Cancer Inst* 2000 ; 92 : 699-708.
 - 5) Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, et al. Chemotherapy in advanced ovarian cancer : four systematic meta-analyses of individual patient data from 37 randomized trials. *Advanced Ovarian Cancer Trialists' Group. Br J Cancer* 1998 ; 78 : 1479-87.
 - 6) Ozols RF, Bundy BN, Greer BE, Fowley JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : A Gynecologic Oncology Group Study. *J Clin Oncol* 2003 ; 21 : 3194-200.
 - 7) du Bois A, Lueck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J Natl Cancer Inst* 2003 ; 9 : 1320-9.
 - 8) du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J Natl Cancer Inst* 2003 ; 95 : 1320-9.
 - 9) 安田允, 木村英三, 落合和徳, 多田聖郎, 宇田川康博, 青木大輔, 他, 卵巣癌に対する Paclitaxel と Carboplatin の併用化学療法の Pilot-Phase I Study (JKTB)-推奨用量について-. *癌と化学療法* 2001 ; 28 : 493-8.
 - 10) Kuzuya K, Ishikawa H, Nakanishi T, Kikkawa F, Nawa A, Fujimura H, et al. Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer : a phase I modified continual reassessment method study. *Int J Clin Oncol* 2001 ; 6 : 271-8.
 - 11) 波多江正紀, 大西義孝, 中村俊昭, 中島久良, 森山伸吾, 高尾直大, 他, 卵巣癌に対するパクリタキセル(TAX)とカルボプラチン(CBDCA)の Phase I Study 会議録. *日本癌治療学会誌* 1998 ; 33 : 274.
 - 12) Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer : high-dose versus low-dose and long versus short infusion. *J Clin Oncol* 1994 ; 12 : 2654-66.
 - 13) Young RC, Bell JG, Lage J. A randomized phase III trial of carboplatin (AUC7.5) and paclitaxel 175mg/m² q21 days x3 courses versus the same regimen x6 courses, in patients with selected stage Ic and II (A,B,C) and selected IA and IB ovarian cancer. 2002 GOG Statistical Report.
 - 14) Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol) /carboplatin in early stage ovarian cancer. *Semin Oncol* 2000 ; 27 : 8-10.
 - 15) Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial : two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. *J Natl Cancer Inst* 2003 ; 95 : 105-12.
 - 16) Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International collaborative ovarian neoplasm trial 1 : a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. *J Natl Cancer Inst* 2003 ; 95 : 125-32.
 - 17) Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma : european organisation for research and treatment of cancer- adjuvant chemotherapy in ovarian neoplasm trial. *J Natl Cancer Inst* 2003 ; 95 : 113-25.
 - 18) Murphy D, Crowther D, Renninson J, Prendiville J, Ranson M, Lind M, et al. A randomized dose intensity study in ovarian carcinoma comparing chemotherapy given at four week

- intervals for six cycles with half dose chemotherapy given for twelve cycles. *Ann Oncol* 1993 ; 4 : 377-83.
- 19) Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. *Lancet* 1992 ; 340 : 329-33.
 - 20) Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. *Scottish gynecology cancer trials group. J Clin Oncol* 1996 ; 14 : 2113-9
 - 21) McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer. A gynecologic oncology group study. *J Clin Oncol* 1995 ; 13 : 1589-99.
 - 22) Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer : a randomized study of the Gruppo Oncologico Nord-Ovest. *J Clin Oncol* 1996 ; 14 : 351-6.
 - 23) Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer : A Danish Ovarian Cancer Group Study. *J Clin Oncol* 1997 ; 15 : 193-8.
 - 24) Colombo N, Maggioni A, Vignali M, Parma G, Mangioni C. Options for primary chemotherapy in advanced ovarian cancer : the European perspective. *Gynecol Oncol* 1994 ; 55 : S108-13.
 - 25) Gore M, Mainwaring P, A' Hern R, MacFarlane V, Slevin M, Harper P, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. *London Gynaecological Oncology Group. J Clin Oncol* 1998 ; 16 : 2426-34.
 - 26) Thigpen JT, Dose-intensity in ovarian carcinoma : hold, enough? *J Clin Oncol* 1997 ; 15 : 1291-3.
- C. 寛解導入・補助オプション
- 1) Vasey PA, Survival and longer-term toxicity results of the SCOTROC study : docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). *Proc ASCO* 2002 ; 21 : 202a (804).
 - 2) Wu CH, Yang CH, Lee JN, Hsu SC, Tsai EM. Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. *Int J Gynecol Cancer* 2001 ; 11 : 295-9.
 - 3) Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer : a gynecologic oncology group study. *J Clin Oncol* 2000 ; 18 : 106-15.
 - 4) ICON Group, Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer : the ICON3 randomized trial. *Lancet* 2002 ; 360 : 505-15.
 - 5) Gershenson DM, Morris M, Burke TW, Levenback C, Kavanagh JJ, Fromm GL, et al. : Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. *Gynecol Oncol* 1995 ; 58 : 349-55.
 - 6) 中村俊昭, 大西義孝, 山本文子, 前田隆嗣, 波多江正紀. 上皮性卵巣癌 Stage III・IV 期に対する JP (Carboplatin・Cisplatin) 併用療法の長期予後. *日本癌治療学会誌* 2000 ; 35 : 555
 - 7) Sugiyama T, Yakushiji M, Kamura T, Ikeda M, Umesaki N, Hasegawa K, et al. Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. *Oncology* 2002 ; 63 : 16-22
- D. 留意事項
- 1) Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, et al. Sequences of taxol and cisplatin : a phase I and pharmacologic study. *J Clin Oncol* 1991 ; 9 : 1692-703.

- 2) Calvert AH, Egorin MJ. Carboplatin dosing formulae : gender bias and the use of creatinine-based methodologies. *Eur J Cancer* 2002 ; 38 : 11-6.
- 3) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976 ; 16 : 31-41.
- 4) Jelliffe RW, Letter : Creatinine clearance : bedside estimate. *Ann Intern Med* 1973 ; 79 : 604-5.
- 5) Dupont JS, Soignet SL, Spriggs DR. General principles of chemotherapy. In : Barakat RR, Bevers MW, Gershenson DM, Hoskins WJ, editors. *Handbook of Gynecologic Oncology*. 2nd ed. London. Martin Dunitz 2002 ; 47-76.
- 6) Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldboom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. *J Clin Oncol* 1992 ; 10 : 520-8.
- 7) Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, et al. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. *European Lung Cancer Working Party. Eur J Cancer* 1999 ; 35 : 1314-9.
- 8) Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. *J Clin Oncol* 1999 ; 17 : 1141.
- 9) Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, et al. Successful re-treatment with taxol after major hypersensitivity reactions. *J Clin Oncol* 1993 ; 11 : 885-90.
- 10) Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. *Ann Oncol* 1997 ; 8 : 611-4.

E. 支持療法

- 1) 日本癌治療学会臨床試験委員会 : G-CSF 適正使用ガイドライン. *Int J Clinical Oncol* 2001 ; 6 (Suppl) : 1-24.
- 2) American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony - stimulation factors : evidence - based, clinical practice guidelines. *J Clin Oncol* 1994 ; 12 : 2471-508.
- 3) Update of recommendations for the use of hematopoietic colony - stimulating factors : evidence-based clinical practice guidelines. American Society of Clinical Oncology. *J Clin Oncol* 1996 ; 14 : 1957-60.
- 4) Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of hematopoietic colony-stimulating factors : Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. *J Clin Oncol* 1999 ; 17 : 3676 - 81.
- 5) Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med* 1966 ; 64 : 328-40.
- 6) Gaviria JM, Garrido SM, Root RK. Clinical use of granulocyte colony-stimulating factor in infectious diseases. *Curr Clin Top Infect Dis* 2001 ; 21 : 302-22.
- 7) Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors : evidence-based, clinical practice guidelines. *J Clin Oncol* 2000 ; 18 : 3558-85.
- 8) Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. *J Clin Oncol* 1997 ; 15 : 2981- 95.
- 9) Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. *J Clin Oncol* 1998 ; 16 : 3179-90.
- 10) Bokemeyer C, Kuczyk MA, Kohne H, Einsele H, Kynast B, Schmoll HJ. Hematopoietic growth factors and treatment of testicular cancer : biological interactions, routine use and dose-intensive chemotherapy. *Ann Hematol* 1996 ; 72 : 1-9.
- 11) Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations

for the use of antiemetics : evidence-based, clinical practice guidelines. *J Clin Oncol* 1999 ; 17 : 2971-94.

F. 術前化学療法

- 1) Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. *Gynecol Oncol* 1990 ; 37 : 327-31.
- 2) 清水敬生, 荷見勝彦. FIGO III・IV期悪性卵巣腫瘍に対する治療成績—Neoadjuvant 化学療法は有用か?—. *日産婦誌* 1993 ; 45 : 1007-14.
- 3) Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecol Oncol* 1994 ; 53 : 33-7.
- 4) Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. *Eur J Gynaecol Oncol* 1996 ; 17 : 393-6.
- 5) Zylberberg B, Dormont D, Jankiewicz S, Darai E, Bretel JJ, Poncelet C, et al. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. *Eur J Gynaecol Oncol* 2001 ; 22 : 40-5.
- 6) Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIc ovarian carcinoma. *Cancer* 2001 ; 92 : 2585-91.
- 7) Vrscaj MU, S.Rakar. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma : A retrospective case-control study. *Eur J Gynaecol Oncol* 2002 ; 23 : 405-10.
- 8) Ushijima K, Ota S, Komai K, Matsuo G, Motoshima S, Honda S et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. *Int Surg* 2002 ; 87 : 185-90.
- 9) Fruehauf JP, Yu IR, Parker R. In vitro drug response and biomaker profiles for ovarian cancer specimens obtained at initial debulking or after neoadjuvant chemotherapy (EORTC 55971) . *Proc ASCO* 2002 ; 21 : 91b (2177) .

G. 維持科学療法

- 1) Young RC, Brady MF, Nieberg RM, Long HJ, Mayer AR, Lentz SS, et al. Adjuvant treatment for early ovarian cancer : a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—a gynecologic oncology group study. *J Clin Oncol* 2003 ; 2 : 4350-5.
- 2) Trope C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. *Ann Oncol* 2000 ; 11 : 281-8.
- 3) Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, et al. Adjuvant treatment for early epithelial ovarian cancer : results of two randomized clinical trials comparing cisplatin to no further treatment or chronic phosphate (32P) . *GICOG. Ann Oncol* 1995 ; 6 : 887-93.
- 4) Mannel R, Kohn EC, Michael H. A randomized phase III trial of iv carboplatin (AUC6) and paclitaxel 175mg/mm q21days x3 courses plus low dose paclitaxel 40mg/mm/wk versus iv carboplatin (AUC6) and paclitaxel 175mg/mm q21days x3 courses plus observation in patients with early stage ovarian carcinoma. *GOG protocol175. Gynecologic Oncology Group statistical report* 2004 ; 402.
- 5) Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD , et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy : A Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol* 2003 ; 21 : 2460-5.
- 6) Barakat RR, Almadrone L, Venkatraman ES, Aghajanian C, Brown C, Shapiro F, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II - IV epithelial ovarian cancer following negative surgical assessment. *Gynecol*

- Oncol 1998 ; 69 : 17-22.
- 7) Cure H, Battista C, Guastalla J, Fabbro M, Tubiana-Mathieu N, Bourgeois H, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC) : Preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc ASCO 2001 ; 204a.
 - 8) Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992 ; 45 : 284-9.
 - 9) Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer : A Danish ovarian study group trial (DACOVA) . Gynecol Oncol 1993 ; 49 : 30-6.
 - 10) Boruta DM, Fowler WC, Gehrig PA, Boggess JF, Walton LA, VanLe L. Weekly paclitaxel infusion as consolidation therapy in ovarian cancer. Proc ASCO 2002 ; 21 : 215a (856) .
 - 11) Chiara S, Lionetto R, Campora E, Oliva C, Merlini L, Bruzzi P, et al. Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest. Eur J Cancer 1995 ; 31 : 296-301.

H. 腹腔内化学療法

- 1) Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982 ; 97 : 845-51.
- 2) Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 ; 335 : 1950-5.
- 3) Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma : an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001 ; 19 : 1001-7.
- 4) Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC) : a Gynecologic Oncology Group Trial (GOG 172) . Proc ASCO 2002 ; 21 : 201a (803) .
- 5) Rubin SC, Hoskins WJ, Markman M, Hakes T, Lewis JL Jr. Long-term access to the peritoneal cavity in ovarian cancer patients. Gynecol Oncol 1989 ; 33 : 46-8.
- 6) Adachi S, Noda T, Ito K, Kiyozuka Y, Itani Y, Shintani M, et al. Complications associated with CDDP intraperitoneal chemotherapy. Asia-Oceania J Obstet Gynaecol 1994 ; 20 : 7-12.

I. その他

- 1) Shinozuka T, Miyamoto T, Muramatsu T, Hirasawa T, Murakami M, Makino T, et al. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma : long term results for 105 patients. Cancer 1999 ; 85 : 1555-64.
- 2) Benedetti-Panici P, Greggi S, Scambia G, Salerno MG, Menichella G, Pierelli L, et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 1995 ; 27 : 133-8.
- 3) Thigpen JT. Dose-intensity in ovarian carcinoma : hold, enough? J Clin Oncol 1997 ; 15 : 1291-3.
- 4) Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O'Flaherty C, et al. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

J Clin Oncol 1998 ; 16 : 1852-60.

V. 境界悪性腫瘍(上皮性)の治療—フローチャートとその解説—

- 1) Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. *Gynecol Oncol* 1993 ; 51 : 236-43.
- 2) Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. *Cancer* 1993 ; 71 : 1810-20.
- 3) Barnhill DR, Kurman RJ, Brady MF, Omura GA, Yordan E, Given FT, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential : A Gynecologic Oncology Group study. *J Clin Oncol* 1995 ; 13 : 2752-6.
- 4) Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. *Gynecol Oncol* 2002 ; 86 : 34-7.
- 5) Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. *Gynecol Oncol* 1991 ; 42 : 124-30.
- 6) Fort MG, Pierce VK, Saigo PE, Hoskins WJ, Lewis JL Jr. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. *Gynecol Oncol* 1989 ; 32 : 269-72.
- 7) Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study) . *Gynecol Oncol* 1991 ; 41 : 230-3.
- 8) Barakat RR, Benjamin I, Lewis JL Jr, Saigo PE, Curtin JP, Hoskins WJ. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. *Gynecol Oncol* 1995 ; 59 : 390-3.

VI. 初回治療後のフォローアップ

- 1) Ovarian Cancer Guideline (Version 1.2002) . National Comprehensive Cancer Network.
- 2) 河野一郎, 藤原恵一, 鈴木幸子. 再発卵巣癌の診断と治療. *癌の臨床* 1997 ; 43 : 1363-9.
- 3) Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. *J Epidemiol Biostat* 2001 ; 6 : 107-38.
- 4) Niloff JM, Bast RC Jr, Schaetzl EM, Knapp RC. Predictive value of CA125 antigen levels in second-look procedures for ovarian cancer. *Am J Obstet Gynecol* 1985 ; 151 : 981-6.
- 5) Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? *Gynecol Oncol* 1993 ; 49 : 3-7.
- 6) Meier W, Baumgartner L, Stieber P, Hasholzner U, Fateh-Maghadam A. CA125 based diagnosis and therapy in recurrent ovarian cancer. *Anticancer Res* 1997 ; 17 : 3019-20.
- 7) 津村宜彦, 櫻木範明, 田中俊誠, 藤本征一郎. 原発性上皮性卵巣癌再燃における血中 CA-125 値の正常範囲内変動の意義について. *産婦人科治療* 1990 ; 61 : 854-9.
- 8) Gard GB, Houghton CR. An assessment of the value of serum CA125 measurement in the management of epithelial ovarian carcinoma. *Gynecol Oncol* 1994 ; 53 : 283-9.
- 9) 市村友季, 金岡靖, 梅咲直彦, 辰田一郎, 川村直樹, 本田謙一, 他, 再発の診断および予後の予知因子としての CA125 値の検討. *産婦人科* 1995 ; 47 : 591-3.
- 10) Sugiyama T, Nishida T, Komai K, Nishimura H, Yakushiji M, Nishimura H. Comparison of CA125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. *Int J Gynecol Obstet* 1996 ; 54 : 251-6.
- 11) 三好端, 薬師寺道明. 各種腫瘍マーカーのカット・オフ値. *OncoI Chemother* 1990 ; 5 : 301-5

VII. 再発卵巣癌の治療—フローチャートとその解説—

- 1) Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. *J Clin*